Revatis S.A. • Production and supply of human stem cells
Revatis focuses on R&D projects, preclinical studies, non-therapeutic applications and tissue engineering.
Research & DevelopmentProduction of muscle derived mesenchymal stem cells
By using its innovative, minimally invasive and patented technology for obtaining multipotent stem cells, Revatis is able to provide its partners with an affordable and reliable supply of stem cells for their R&D and preclinical applications.
Less invasive sampling facilitates autologous use and personalized medicine applications, both diagnostic and tissue engineering such as 3D bioprinting.
Cell production in aseptic isolator, quality management system and GMP certification ensure stable and high quality supply.
The team is very experienced in the differentiation, culture, production and quality control of stem cells as well as in the management of research projects.
Revatis shares patents, knowledge and know-how with its partners.
Muscle derived mesenchymal stem cells
The stem cells developed by Revatis exhibit high multipotency, remarkable paracrine effects and immunomodulatory properties targeting not only lymphocytes, macrophages but also neutrophils.
Revatis technology provides a population of stem cells that comply with the guidelines of the International Society for Cell Therapy (ISCT).
The creation of a network for R&D
Revatis is positioned at the center of a network of partners using the stem cells in various fundamental, applied and preclinical research projects.
Biobanking
Revatis has an accredited biobank of stem cells for R & D from muscle biopsies performed on healthy volunteers.
Therapeutic use
Revatis establishes agreements with human body material banks to position itself as an "intermediate structure" for the production of clinical batches for immediate or deferred use
Our team
Benjamin Damien
Business Development
Didier Serteyn
CEO
Justine Ceusters
CSO/COO
Hélène Graide
Production Management
Julien Duysens
Production Assistant
Ambitions and objectives
Our ambition is to become a major player in the use of cell therapy in personalized medicine. Our objective is to use the results of clinical studies in animals as a preclinical study in humans.